NO994042L - Transdermal anordning til levering av testosteron - Google Patents

Transdermal anordning til levering av testosteron

Info

Publication number
NO994042L
NO994042L NO994042A NO994042A NO994042L NO 994042 L NO994042 L NO 994042L NO 994042 A NO994042 A NO 994042A NO 994042 A NO994042 A NO 994042A NO 994042 L NO994042 L NO 994042L
Authority
NO
Norway
Prior art keywords
testosterone
delivery
transdermal device
transdermal
terpene
Prior art date
Application number
NO994042A
Other languages
English (en)
Norwegian (no)
Other versions
NO994042D0 (no
Inventor
John C Hedenstrom
Michael L Husberg
Shari L Myszka
Matthew T Scholz
Original Assignee
Minnesota Mining & Mfg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minnesota Mining & Mfg filed Critical Minnesota Mining & Mfg
Publication of NO994042D0 publication Critical patent/NO994042D0/no
Publication of NO994042L publication Critical patent/NO994042L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
NO994042A 1997-02-28 1999-08-20 Transdermal anordning til levering av testosteron NO994042L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3927497P 1997-02-28 1997-02-28
PCT/US1998/003943 WO1998037871A1 (fr) 1997-02-28 1998-02-27 Dispositif transdermique d'administration de testosterone

Publications (2)

Publication Number Publication Date
NO994042D0 NO994042D0 (no) 1999-08-20
NO994042L true NO994042L (no) 1999-10-26

Family

ID=21904596

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994042A NO994042L (no) 1997-02-28 1999-08-20 Transdermal anordning til levering av testosteron

Country Status (16)

Country Link
US (1) US6132760A (fr)
EP (1) EP0979072B1 (fr)
JP (1) JP2001517216A (fr)
KR (1) KR20000075804A (fr)
AT (1) ATE293960T1 (fr)
AU (1) AU735944B2 (fr)
BR (1) BR9807786A (fr)
CA (1) CA2281876A1 (fr)
DE (1) DE69829961T2 (fr)
HU (1) HUP0001748A3 (fr)
NO (1) NO994042L (fr)
NZ (1) NZ337135A (fr)
PL (1) PL335410A1 (fr)
SK (1) SK116199A3 (fr)
TR (1) TR199902104T2 (fr)
WO (1) WO1998037871A1 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2793689B1 (fr) * 1999-05-19 2001-08-24 Pf Medicament Dispositif transdermique pour l'administration de testosterone ou d'un de ses derives
US6586000B2 (en) 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6673363B2 (en) 1999-12-16 2004-01-06 Dermatrends, Inc. Transdermal and topical administration of local anesthetic agents using basic enhancers
US6562369B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers
US20030104041A1 (en) * 1999-12-16 2003-06-05 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US6582724B2 (en) 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
KR100940245B1 (ko) * 2000-09-19 2010-02-04 내쇼날 스타치 앤드 케미칼 인베스트멘트 홀딩 코포레이션 경피 약물 전달 시스템에 유용한 비반응성 접착제
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
JP4489356B2 (ja) * 2001-05-11 2010-06-23 メリオン リサーチ スリー リミテッド 浸透促進剤
KR100517637B1 (ko) * 2001-12-21 2005-09-28 씨제이 주식회사 섬수 정제 엑스 및 인삼 정제 엑스를 함께 함유하면서다른 정유 생약 성분은 함유하지 않는 조루증의 예방 및치료용 조성물
US20040062794A1 (en) * 2002-09-30 2004-04-01 Lee Shulman 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy
IL152573A (en) 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
EA009623B1 (ru) 2003-04-30 2008-02-28 Пэдью Фарма Л.П. Устойчивая к манипуляциям дозировочная форма для трансдермального введения
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
AU2004249295A1 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating HIV
CA2546200A1 (fr) * 2003-11-18 2005-06-02 3M Innovative Properties Company Compositions d'administration medicamenteuse transdermique renfermant de l'olanzapine
JP4567998B2 (ja) * 2004-03-22 2010-10-27 コスメディ製薬株式会社 親水性粘着剤を用いた親水性皮膚外用粘着剤組成物および親水性貼付剤
BRPI0617294B8 (pt) 2005-10-12 2021-05-25 Besins Healthcare Lu Sarl composição farmacêutica em gel hidroalcóolico e uso de testosterona
US20080132475A1 (en) * 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
US20100016264A1 (en) * 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
FR2924942B1 (fr) * 2007-12-14 2012-06-15 Pf Medicament Compositions pharmaceutiques transcutanees contenant une hormone steroidienne
US8445037B2 (en) * 2008-10-28 2013-05-21 A. M. Todd Company Volatile distillate by-product of mint oil that promotes absorption and/or bioavailability of compounds of bio-medical and nutritional interest
JP6912852B2 (ja) 2010-11-18 2021-08-04 ホワイト マウンテン ファーマ,インコーポレイテッド 対象における慢性または解決不能な疼痛を処置するための、および/または痛覚閾値を高めるための方法、およびこれに用いる医薬組成物
CN105916951A (zh) * 2013-12-20 2016-08-31 3M创新有限公司 抗菌压敏粘合剂体系
UY35923A (es) * 2013-12-30 2015-07-31 Rhodia Operations ?composiciones pesticidas agrícolas?.
US11813354B1 (en) 2019-01-11 2023-11-14 Shear Kershman Laboratories, Inc Trans-mucosal delivery system for testosterone

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU622162B2 (en) * 1988-04-22 1992-04-02 Ciba-Geigy Ag Transdermal monolith systems
AU6712090A (en) * 1989-10-13 1991-05-16 Watson Laboratories, Inc. Drug delivery systems and matrix therefor
ES2094809T3 (es) * 1990-03-30 1997-02-01 Yasunori Morimoto Composicion absorbible por via percutanea del clorhidrato de morfina.
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
EP0491076A1 (fr) * 1990-12-19 1992-06-24 Theratech, Inc. Augmentation de la pénétration avec un système à composants multiples contenant des pyrrolidones N-aliphatiques avec des alcools inférieurs
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
US5340586A (en) * 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
DE4210165A1 (de) * 1991-07-30 1993-02-04 Schering Ag Transdermale therapeutische systeme
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
US5230897A (en) * 1991-10-31 1993-07-27 G. D. Searle & Co. Transdermal pentamidine
CA2075517C (fr) * 1992-04-01 1997-03-11 John Wick Piece transdermique incorporant une pellicule de polymeres incorporee a l'aide d'un agent actif
JP3548195B2 (ja) * 1993-05-27 2004-07-28 リンテック株式会社 経皮吸収型製剤
US5460820B1 (en) * 1993-08-03 1999-08-03 Theratech Inc Method for providing testosterone and optionally estrogen replacement therapy to women
JP3908795B2 (ja) * 1994-11-29 2007-04-25 久光製薬株式会社 ケトチフェン含有経皮投与製剤

Also Published As

Publication number Publication date
KR20000075804A (ko) 2000-12-26
NZ337135A (en) 2001-07-27
AU6539098A (en) 1998-09-18
PL335410A1 (en) 2000-04-25
CA2281876A1 (fr) 1998-09-03
DE69829961T2 (de) 2006-02-23
US6132760A (en) 2000-10-17
JP2001517216A (ja) 2001-10-02
WO1998037871A1 (fr) 1998-09-03
BR9807786A (pt) 2000-02-22
TR199902104T2 (xx) 2000-04-21
DE69829961D1 (de) 2005-06-02
EP0979072B1 (fr) 2005-04-27
ATE293960T1 (de) 2005-05-15
NO994042D0 (no) 1999-08-20
HUP0001748A2 (hu) 2000-12-28
AU735944B2 (en) 2001-07-19
EP0979072A1 (fr) 2000-02-16
HUP0001748A3 (en) 2001-03-28
SK116199A3 (en) 2000-01-18

Similar Documents

Publication Publication Date Title
NO994042L (no) Transdermal anordning til levering av testosteron
CA2278714A1 (fr) Dilatateur nasal medicalise a montage externe
KR960702300A (ko) 에스트라디올을 함유하는 경피 치료 시스템 (transdermal therapeutic system containing estradiol)
AU579970B2 (en) Self-adhesive plaster containing medication
PT941078E (pt) Metodo e dispositivo para o revestimento de substratos para utilizacao farmaceutica
PL324552A1 (en) Plaster for pecutaneous administration of hormones
AU1652997A (en) Transdermal therapeutic systems containing crystallization inhibitors
DK0973497T3 (da) Farmaceutisk bæreanordning, egnet til udlevering af farmaceutiske forbindelser til slimhindeoverflade
ES2147858T3 (es) Matriz para el suministro transdermico de farmacos.
ZA977832B (en) Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents.
AU4948493A (en) Dexpanthenol-containing plaster for the transdermal application of steroid hormones
WO2001050989A8 (fr) Bandage de contact pliable
ES2156220T3 (es) Preparacion transdermica que contiene un metabolito de loratidina con accion antihistaminica.
NO20000921L (no) Fibrinogenbasert vevklebemiddel
AU4657896A (en) Polyisobutylene adhesives containing high TG tackifier for transdermal devices
NO993855L (no) Töyelig transdermalt terapeutisk system
NO993435L (no) Transdermalt acetylsalicylsyre inneholdende terapeutisk system med forsterket resorpsjon
HUP9903340A2 (hu) Trimegeszton transzdermális adagolására szolgáló új eszköz, és eljárás előállítására
DK0767831T3 (da) Sprøjte omfattende et vedhæftende substrat for mikrober
AU8732098A (en) A device and a process for the locating of an interrupt request allocated to a source
AU4015097A (en) Transdermal therapeutic system having an active compound combination comprising oestriol
ES2118690T3 (es) Disco de control para un arrollador de cinturon.
ES2112748A1 (es) Papel de empapelar que se puede aplicar oquitar facialmente de un sustrato.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application